D.N.A Biomedical Solutions Ltd. (TASE:DNA) announced a private placement of 70,100,000 common shares on November 8, 2020. The transaction will include participation from Rosen and Assaf Tochmeir for a total of 51,260,000 common shares representing 50.84% stake in the company in equal parts and institutional investors for 18,740,000 shares representing 18.59% stake in the company. The transaction also included participation from Tony Klein, Chief Financial Officer of the company for 100,000 common shares representing 1% of the company.